Lenalidomide Stada (Lenalidomide)

Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, changing its target profile. This leads to the ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, which suppresses malignant plasma‑cell growth, inhibits new blood‑vessel formation, and enhances immune‑mediated tumor killing.

The specific dose of Lenalidomide Stada is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Dosing regimens may differ between multiple myeloma, MDS with del(5q), and mantle‑cell lymphoma, and should follow the latest approved labeling and clinical guidelines.

Lenalidomide is classified as Pregnancy Category X because it is known to cause fetal harm. It is contraindicated in pregnancy, and effective contraception must be used by both male and female patients of reproductive potential. The drug is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and provides benefits such as oral administration and anti‑angiogenic effects. Compared with older agents like thalidomide, Lenalidomide generally has a more favorable side‑effect profile, especially regarding neuropathy.

Lenalidomide Stada should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Lenalidomide Stada is taken orally, usually once daily, with or without food, as directed by the treating physician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe neutropenia or thrombocytopenia that can lead to infection or bleeding, venous thromboembolism, life‑threatening skin reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, and hepatic failure. Patients should be monitored closely for these events throughout treatment.

Lenalidomide Stada is contraindicated in pregnant women, patients with known hypersensitivity to lenalidomide or any component of the formulation, and individuals who cannot comply with required contraception measures. Caution is also advised for patients with severe renal impairment, uncontrolled infections, or a history of thromboembolic events.